2021/04/29
(SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 (“Reporting Period”).
Read more2021/03/30
(SHANGHAI, March 30, 2021) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 (“Reporting Period”).
Read more2021/03/02
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
Read more2021/02/02
NEW YORK & SHANGHAI -- Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
Read more2020/12/02
SHANGHAI, December 2, 2020 -- WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has received the 2020 Global Customer Value Leadership Award from Frost & Sullivan, a global business research and consulting firm. This marks the fourth consecutive year WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.
Read more